The first day of the World Health Organization (WHO)/ Medicines Patent Pool (MPP) mRNA Technology Transfer 2025 meeting at Kenya BioVax Institute Limited set a strong foundation for advancing Africa’s vaccine manufacturing capabilities.
In her opening remarks, Acting CEO Dr. Cecilia Wanjala emphasized Kenya BioVax’s commitment to strengthening biopharmaceutical self-reliance, recognizing WHO’s leadership in ensuring equitable access to life-saving technologies.
Discussions focused on key enablers for successful #mRNAtechnology adoption, including workforce development, infrastructure readiness, and regulatory alignment. Participants reviewed the progress of the WHO-led initiative, which has already established an mRNA manufacturing platform in South Africa. With Kenya BioVax among the 15 global partners selected for training and capacity-building, the meeting reinforced the country’s role in shaping regional vaccine production and fostering innovation in global health security.
